Concepts of epigenetics in prostate cancer development
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Substantial evidence now supports the view that epigenetic changes have a role in the development of human prostate cancer. Analyses of the patterns of epigenetic alteration are providing important insights into the origin of this disease and have identified specific alterations that may serve as useful diagnostic and prognostic biomarkers. Examination of cancer methylation patterns supports a stem cell origin of prostate cancer. It is well established that methylation of GSTpi is a marker of prostate cancer, and global patterns of histone marking appear to be linked to cancer prognosis with levels of acetylated histones H3K9, H3K18, and H4K12, and of dimethylated H4R3 and H3K4, dividing low-grade prostate cancer (Gleason 6 or less) into two prognostically separate groups. Elevated levels of several components of the polycomb group protein complex, EZH2, BMI1, and RING1, can also act as biomarkers of poor clinical outcome. Many components of the epigenetic machinery, including histone deacetylase (whose expression level is linked to the TMPRSS2:ERG translocation) and the histone methylase EZH2, are potential therapeutic targets. The recent discovery of the role of small RNAs in governing the epigenetic status of individual genes offers exciting new possibilities in therapeutics and chemoprevention.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Epigenetic differences arise during the lifetime of monozygotic twins
Fraga, M. F., Ballestar, E., Paz, M. F., Ropero, S., Setien, F., Ballestar, M. L., Heine-Suñer, D., Cigudosa, J. C., Urioste, M., Benitez, J., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0500398102 · Cited by 3,602
Schlesinger, Y., Straussman, R., Keshet, I., Farkash, S., Hecht, M., Zimmerman, J., Eden, E., Yakhini, Z., Ben-Shushan, E., Reubinoff, B. E., et al. (2007) · Nature Genetics · doi:10.1038/ng1950 · Cited by 1,226
Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon
Issa, J.-P. J., Ottaviano, Y. L., Celano, P., Hamilton, S. R., Davidson, N. E., & Baylin, S. B. (1994) · Nature Genetics · doi:10.1038/ng0894-536 · Cited by 1,191 · cited 2×
“Inactivation of specific genes by DNA methylation in the ageing colonic mucosa has been proposed to be one of the earliest events in the development of cancer at this site (Issa et al, 1994).”
BackgroundSex-specific, male-line transgenerational responses in humans
The ALSPAC Study Team, Pembrey, M. E., Bygren, L. O., Kaati, G., Edvinsson, S., Northstone, K., Sjöström, M., & Golding, J. (2006) · European Journal of Human Genetics · doi:10.1038/sj.ejhg.5201538 · Cited by 1,150 · cited 2×
“Future studies will need to address why DNA methylation in cancer affects some silenced PcG targets but not others.”
BackgroundOhm, J. E., McGarvey, K. M., Yu, X., Cheng, L., Schuebel, K. E., Cope, L., Mohammad, H. P., Chen, W., Daniel, V. C., Yu, W., et al. (2007) · Nature Genetics · doi:10.1038/ng1972 · Cited by 1,130 · cited 2×
“Model taken from the data presented by Ohm et al (2007) and Schlesinger et al (2007).”
BackgroundMethodHDACs, histone deacetylation and gene transcription: from molecular biology to cancer therapeutics
Gallinari, P., Marco, S. D., Jones, P., Pallaoro, M., & Steinkühler, C. (2007) · Cell Research · doi:10.1038/sj.cr.7310149 · Cited by 678 · cited 1×
“Clinical trials have, however, been largely restricted to cancer types other than prostate (Gallinari et al, 2007).”
BackgroundKurukuti, S., Tiwari, V. K., Tavoosidana, G., Pugacheva, E., Murrell, A., Zhao, Z., Lobanenkov, V., Reik, W., & Ohlsson, R. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0600326103 · Cited by 511 · cited 2×
“Cancer formation is accompanied by dramatic changes in the cellular methylation profile such that global demethylation of the genome occurs in parallel with CpG hypermethylation at specific genes strongly linked to their transcriptional inactivation.”
Background
Cited by
Immunity, Inflammation, and Cancer
Grivennikov, S. I., Greten, F. R., & Karin, M. (2010) · Cell · doi:10.1016/j.cell.2010.01.025 · Cited by 10,755
The inflammation highway: metabolism accelerates inflammatory traffic in obesity
Johnson, A. R., Justin Milner, J., & Makowski, L. (2012) · Immunological Reviews · doi:10.1111/j.1600-065x.2012.01151.x · Cited by 603
“Continuous secretion of pro-inflammatory cytokines by activated immune cells not only sustains ROS production but also can elicit epigenetic changes in premalignant cells stemming from aberrant DNA methylation-driven and microRNA-mediated gene silencing, particularly in tumor suppressor genes (255).”
BackgroundInflammation and oncogenesis: a vicious connection
Grivennikov, S. I., & Karin, M. (2010) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2009.11.004 · Cited by 456
Role of Epigenetics in Biology and Human Diseases.
Moosavi, A., & Ardekani, A. M. (2016) · PubMed · doi:10.22045/ibj.2016.01 · Cited by 273
Shu, L., Khor, T. O., Lee, J.-H., Boyanapalli, S. S. S., Huang, Y., Wu, T.-Y., Saw, C. L.-L., Cheung, K.-L., & Kong, A.-N. T. (2011) · The AAPS Journal · doi:10.1208/s12248-011-9300-y · Cited by 187
Metadata
- Authors
- Cooper, C. S., & Foster, C. S.
- Venue
- British Journal of Cancer
- Published
- 2008-11-11
- Volume
- 100
- Issue
- 2
- Pages
- 240-245
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2034356514
- Cited by
- 108
- References
- 7
- FWCI
- 4.22
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Concepts of epigenetics in prostate cancer development. https://app.cochat.ai/papers/10.1038/sj.bjc.6604771
- The paper
- Cooper, C. S., & Foster, C. S. (2009). Concepts of epigenetics in prostate cancer development. British Journal of Cancer. https://doi.org/10.1038/sj.bjc.6604771
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.